MX2020006237A - Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4. - Google Patents

Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4.

Info

Publication number
MX2020006237A
MX2020006237A MX2020006237A MX2020006237A MX2020006237A MX 2020006237 A MX2020006237 A MX 2020006237A MX 2020006237 A MX2020006237 A MX 2020006237A MX 2020006237 A MX2020006237 A MX 2020006237A MX 2020006237 A MX2020006237 A MX 2020006237A
Authority
MX
Mexico
Prior art keywords
compounds
treatment
diseases related
dux4 expression
dux4
Prior art date
Application number
MX2020006237A
Other languages
English (en)
Inventor
Monika Ermann
Marcus Geese
Martin Schneider
Maeyer Joris De
Sebastian Monecke
Alexander Kaever
Timothy Robin James
Original Assignee
Facio Intellectual Property B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Facio Intellectual Property B V filed Critical Facio Intellectual Property B V
Publication of MX2020006237A publication Critical patent/MX2020006237A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a compuestos para el tratamiento de enfermedades relacionadas con la expresión de DUX4, tales como distrofias musculares. También se refiere al uso de tales compuestos, o a métodos de uso de tales compuestos.
MX2020006237A 2017-12-13 2018-12-13 Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4. MX2020006237A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17207162 2017-12-13
PCT/EP2018/084802 WO2019115711A1 (en) 2017-12-13 2018-12-13 Compounds for treatment of diseases related to dux4 expression

Publications (1)

Publication Number Publication Date
MX2020006237A true MX2020006237A (es) 2020-11-06

Family

ID=60673528

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020006237A MX2020006237A (es) 2017-12-13 2018-12-13 Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4.

Country Status (13)

Country Link
US (3) US10973820B2 (es)
EP (2) EP3723756A1 (es)
JP (1) JP2021506765A (es)
KR (1) KR20200098536A (es)
CN (1) CN111479570A (es)
AU (1) AU2018382974A1 (es)
CA (1) CA3083975A1 (es)
DK (1) DK3498278T3 (es)
ES (1) ES2791539T3 (es)
IL (1) IL275321A (es)
MX (1) MX2020006237A (es)
WO (1) WO2019115711A1 (es)
ZA (1) ZA202003407B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016149756A1 (en) 2015-03-23 2016-09-29 The University Of Melbourne Treatment of respiratory diseases
US10973820B2 (en) * 2017-12-13 2021-04-13 Facio Intellectual Property B.V. Compounds for treatment of diseases related to DUX4 expression
AU2019374731B2 (en) 2018-11-07 2025-08-21 Tianli Biotech Pty Ltd Compounds and compositions for the treatment of respiratory diseases
TW202112368A (zh) * 2019-06-13 2021-04-01 荷蘭商法西歐知識產權股份有限公司 用於治療有關dux4表現之疾病的抑制劑組合
WO2021105474A1 (en) * 2019-11-29 2021-06-03 Facio Intellectual Property B.V. New compounds for treatment of diseases related to dux4 expression
CA3159239A1 (en) * 2019-11-29 2021-06-03 Pui Leng Loke Novel compounds for treatment of diseases related to dux4 expression
EP4126878A4 (en) * 2020-03-27 2024-07-10 Gritscience Biopharmaceuticals Co., Ltd. COMPOUNDS AS CASEIN KINASE INHIBITORS
IL297963A (en) 2020-05-07 2023-01-01 Adorx Therapeutics Ltd Antagonists of the adenosine a2a receptor
AU2021342155A1 (en) 2020-09-11 2023-04-13 Arrowhead Pharmaceuticals, Inc. RNAi agents for inhibiting expression of DUX4, compositions thereof, and methods of use
WO2022115301A1 (en) * 2020-11-24 2022-06-02 Merck Sharp & Dohme Corp. Modified isoindolinones as glucosylceramide synthase inhibitors
GB202019622D0 (en) * 2020-12-11 2021-01-27 Adorx Therapeutics Ltd Antagonist compounds
CN116888126B (zh) * 2020-12-15 2026-03-17 北京原基华毅生物科技有限公司 一种酪蛋白激酶抑制剂的化合物
CN119487030A (zh) * 2022-06-14 2025-02-18 北京原基华毅生物科技有限公司 作为酪蛋白激酶抑制剂的化合物的盐和/或晶形

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100439367C (zh) 2003-12-11 2008-12-03 安万特药物公司 作为酪蛋白激酶Iε抑制剂的取代的1H-吡咯并[3,2-b、3,2-c和2,3-c]吡啶-2-甲酰胺以及相关类似物
FR2918061B1 (fr) * 2007-06-28 2010-10-22 Sanofi Aventis Derives de 6-cycloamino-3-(pyridin-4-yl)imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique.
MX2012004997A (es) 2009-10-28 2012-06-12 Pfizer Derivados de imidazol como inhibidores de la caseina quinasa.
EP3181133B1 (en) * 2010-12-20 2019-07-24 Pfizer Inc Novel fused pyridine compounds as casein kinase inhibitors
EP2546357A1 (en) 2011-07-14 2013-01-16 Erasmus University Medical Center Rotterdam A new classifier for the molecular classification of multiple myeloma.
US20150299807A1 (en) 2012-11-21 2015-10-22 The Johns Hopkins University Genomic classifiers for non-invasive identification of high grade prostate cancer with metastatic potential
ES2489297B1 (es) * 2013-01-22 2015-06-10 Consejo Superior De Investigaciones Científicas (Csic) Benzotiazoles sustituidos y sus aplicaciones terapeuticas para el tratamiento de enfermedades humanas
US9814728B2 (en) 2013-09-20 2017-11-14 Saint Louis University Inhibition of DUX4 expression using bromodomain and extra-terminal domain protein inhibitors (BETi)
JP2017506259A (ja) * 2014-02-03 2017-03-02 イッスム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム・リミテッドＹｉｓｓｕｍ Ｒｅｓｅａｒｃｈ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏｍｐａｎｙ Ｏｆ Ｔｈｅ Ｈｅｂｒｅｗ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｊｅｒｕｓａｌｅｍ Ｌｔｄ． 幹細胞を枯渇させるためのカゼインキナーゼｉ阻害剤の使用
SG11201606427SA (en) 2014-02-07 2016-09-29 Agency Science Tech & Res 2,4,5-tri-substituted azole-based casein kinase 1 inhibitors as inducers for cardiomyogenesis
JP6564406B2 (ja) 2014-06-19 2019-08-21 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ カゼインキナーゼ１デルタ／イプシロン阻害剤としてのイミダゾ−ピリダジン誘導体
US10973820B2 (en) * 2017-12-13 2021-04-13 Facio Intellectual Property B.V. Compounds for treatment of diseases related to DUX4 expression

Also Published As

Publication number Publication date
ES2791539T3 (es) 2020-11-04
AU2018382974A1 (en) 2020-06-18
US10973820B2 (en) 2021-04-13
US20210177847A1 (en) 2021-06-17
EP3723756A1 (en) 2020-10-21
KR20200098536A (ko) 2020-08-20
JP2021506765A (ja) 2021-02-22
ZA202003407B (en) 2022-06-29
CA3083975A1 (en) 2019-06-20
US20190175596A1 (en) 2019-06-13
IL275321A (en) 2020-07-30
US20220226318A1 (en) 2022-07-21
WO2019115711A1 (en) 2019-06-20
EP3498278B1 (en) 2020-03-18
DK3498278T3 (da) 2020-04-20
EP3498278A1 (en) 2019-06-19
CN111479570A (zh) 2020-07-31

Similar Documents

Publication Publication Date Title
ZA201906111B (en) Cyclic di-nucleotides compounds for the treatment of cancer
PH12018502102A1 (en) Pyrrolotriazine compounds as tam inhibitors
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
SA519410320B1 (ar) مركبات فينيل -2-هيدروكسي-أسيتيل أمينو -2-ميثيل-فينيل
EA201891200A1 (ru) Композиции, содержащие бактериальные штаммы
EP3778605A3 (en) Lrrk2 inhibitors and methods of making and using the same
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
MX2018000396A (es) Compuestos aza sustituidos como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak-4).
UA117976C2 (uk) Сполуки амінопіримідинілу як інгібітори jak
SG10201811384TA (en) Mnk inhibitors and methods related thereto
SG10201908028SA (en) Cyclopropylamines as lsd1 inhibitors
PH12016501192A1 (en) Tetrahydropyridopyrazines modulators of gpr6
EP3995581A3 (en) Oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders
EA201692526A1 (ru) Замещенные [1,2,4]триазольные соединения
NZ761519A (en) Nlrp3 modulators
MX2017007188A (es) Compuesto antimicotico.
PH12017501872A1 (en) Methods of treating diseases
PH12016501613B1 (en) Pyrazines modulators of gpr6
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
TN2019000038A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
MX370897B (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades,
MX2019002017A (es) Derivados de sofosbuvir para el tratamiento de la hepatitis c.
MX2019008375A (es) Tiobenzoimidazol como fungicidas.
PH12017501955A1 (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer`s disease